BioSpectator Reporter Jeongmin Jo
Combining stem cell application technology and pain control technology to jointly develop treatments for major spinal diseases including degenerative disc disease and spinal cord injury
CHA University Bundang CHA Hospital announced on the 18th that it has signed a business agreement with RudaCure, a company developing treatments for neuropathic pain, for the 'development of spinal disease regenerative therapeutics.'
Based on this agreement, Bundang CHA Hospital and RudaCure will combine Bundang CHA Hospital's stem cell application regenerative technology with RudaCure's pain control technology to pursue: ▲ development of new spinal disease treatments with pain control and regenerative effects ▲ conducting clinical trials of jointly developed treatments at Bundang CHA Hospital ▲ new drug approval based on joint clinical trials ▲ joint technology transfer and new drug development for industrialization of spinal disease treatments.
Jaehua Kim, Director of Bundang CHA Hospital, stated, "Through this agreement between Bundang CHA Hospital, which has strengths in stem cell research for major spinal diseases such as degenerative disc disease and spinal cord injury, and RudaCure, which specializes in pain treatment new drug development, we look forward to creating cases of innovative treatment technology for spinal diseases."